Role of in vitro metabolic interactions in the conduct of drug-drug interaction (DDI) studies.

被引：0
|
作者：
Yuan, R [1 ]
Balian, JD [1 ]
Svadjian, R [1 ]
Uppoor, RS [1 ]
Ajayi, F [1 ]
Burnett, A [1 ]
Lesko, LJ [1 ]
Marroum, P [1 ]
机构：
[1] US FDA, Ctr Drug Evaluat & Res, Off Clin Pharmacol & Biopharm, Rockville, MD 20857 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1998年 / 63卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII46
引用
收藏
页码：218 / 218
页数：1
相关论文
共 50 条
  • [1] A survey of drug-drug interaction (DDI) studies.
    Marroum, P
    Burnett, A
    Svadjian, R
    Uppoor, RS
    Ajayi, F
    Yuan, R
    Lesko, LJ
    Balian, JD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 147 - 147
  • [2] Most common interactant drugs in drug-drug interaction (DDI) studies.
    Uppoor, RS
    Marroum, P
    Burnett, A
    Ajayi, F
    Yuan, R
    Svadjian, R
    Balian, JD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 147 - 147
  • [3] The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, SR
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (05): : 443 - 469
  • [4] SSI-DDI: substructure-substructure interactions for drug-drug interaction prediction
    Nyamabo, Arnold K.
    Yu, Hui
    Shi, Jian-Yu
    BRIEFINGS IN BIOINFORMATICS, 2021, 22 (06)
  • [5] THE PREDICTION OF METABOLIC DRUG-DRUG INTERACTIONS FROM IN VITRO DATA
    Tucker, G.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 1 - 1
  • [6] Synthesis of stable isotopically labelled internal standards for drug-drug interaction (DDI) studies
    Zimmermann, J.
    Allen, J.
    Atzrodt, J.
    De-Bruin, B.
    Derdau, V.
    Gantz, D.
    Herbert, J.
    Raddatz, S.
    Roy, S.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2007, 50 (13-14): : 1277 - 1278
  • [7] Drug-Drug Interaction (DDI) Due to the Inhibition of Fusidic Acid
    Shi, Yun
    LATIN AMERICAN JOURNAL OF PHARMACY, 2017, 36 (09): : 1736 - 1738
  • [8] Synthesis of stable isotope labelled internal standards for drug-drug interaction (DDI) studies
    Atzrodt, J.
    Blankenstein, J.
    Brasseur, D.
    Calvo-Vicente, S.
    Denoux, M.
    Derdau, V.
    Lavisse, M.
    Perard, S.
    Roy, S.
    Sandvoss, M.
    Schofield, J.
    Zimmermann, J.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (18) : 5658 - 5667
  • [9] The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, RS
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) : 815 - 832
  • [10] Drug-Drug Interaction (DDI) of Eslicarbazepine Acetate with Antiepileptic Drugs
    Blum, David
    Nunes, Teresa
    Maier, Gary
    Versavel, Mark
    Zummo, Jacqueline
    Kharidia, Jahnavi
    Soares-da-Silva, Patricio
    NEUROLOGY, 2011, 76 (09) : A287 - A287
12345